New data bolster Stelara's case for shift to first-line psoriasis treatment
This article was originally published in Scrip
Executive Summary
Additional positive data on one of Janssen's (Johnson & Johnson) key future growth drivers, the biological psoriasis treatment Stelara (ustekinumab), are helping to create the mood music that could ease its passage into first-line therapy.